Skip to main content
fghjkjhb

Evidence gap analysis

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

2025 Swedish NordDRG system released

In November 2024, the annual update of the Swedish version of the NordDRG system was published to come into force on January 1, 2025. 

No new DRGs were introduced. Two DRGs were removed. No significant changes were implemented in the DRG grouping logic. In 2025, there is a total of 1978 DRGs, of which 809 are for specialized inpatient care, 653 for specialized outpatient care, and 516 for primary care.

The DRG cost weights were published as well. In 2025, cost weights must be multiplied by a base rate of 88,061 SEK to obtain DRG tariffs.

See the full details in Swedish here (codes) and here (cost weights).

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.

Tags